



March 28, 2022

BSE Limited
P. J. Towers
Dalal Street,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E), Mumbai - 400 051

Dear Sirs,

Sub.: Intimation of Investor/ Analyst Meetings

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be participating in 'Axis Capital India Chemicals Conference 2022' Virtual Investor Conference on Tuesday, March 29, 2022. We enclose names of the Investors/Analysts participating in the same.

The schedule may undergo change due to exigencies on the part of Investors/Analysts/Company.

We also enclose the presentation to be used during the e-conference.

This is for your information and record.

Thanking you,

Yours faithfully,
For Jubilant Ingrevia Limited

Deepanjali Gulati
Company Secretary
Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657



JUBILANT INGREVIA

Sr. No	Investors
1	Fidelity
2	Mirae Mutual Fund
3	Myriad Asset Management Limited
4	Sundaram Mutual Fund
5	Deep Finance

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657



**JUBILANT
INGREVIA**

Investor Presentation

February 2022

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Effective 1st February 2021, Life Science Ingredients business of Jubilant Phormova Limited (earlier Jubilant Life Sciences Limited) demerged to Jubilant Ingrevia Limited and post demerger the consolidated financial results of the Jubilant Ingrevia Limited for the quarter and the year ended 31 March 2021 comprised results only for two months of operations, starting from 1st February 2021 .

To provide the comprehensive picture of the operations of the Company on continuing basis the results for previous periods has been presented on Pro-forma basis by using relevant portion of the published results of LSI Segment - Jubilant Pharmova Limited on Pro-forma basis as Under :

- **Results for Q3'FY21, and 9M'FY21 has been derived on Pro-forma basis from the reported discontinued operations results for LSI segment of Jubilant Pharmova Limited.**
- **As explained in the Financial Results presentation deck for Q4'FY21 we had earlier presented results for full year FY 21 on Pro-forma basis by combining the results from 01 April 2020 to 31 January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited and results for Q4'FY21 on Pro-forma basis by combining the results for January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited**
- **EPS for previous periods has been computed assuming existence of share capital throughout the period**

NOTES:

1. *The numbers for the quarter and Nine Months have been reclassified and regrouped wherever necessary*
2. *Closing Exchange Rate for USD 1 at Rs 73.11 as on March 31, 2021 and Rs 74.33 as on December 31, 2021*

Company Overview



Jubilant Bhartia Group - Snapshot


Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India



Strong presence in diverse sectors like Pharmaceuticals, CDMO (Contract Research & Development Services) and Therapeutics, Specialty Chemicals, Nutraceutical Products and other Life Science Products, Performance Polymers, Food Service (QSR), Auto, Consulting in Aerospace and Oilfield Services




Global presence through investments in India, USA, Canada, Europe, Singapore, China, Sri Lanka and Bangladesh



Employs around 46,000 people across the globe with Over 2,400 in North America

Business Segments & Integrated Operations

Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customized products and solutions



Integrated Operations...

Vertical integration across the value chain enables cost competitive advantage

Nutrition & Health Solutions

- For Vitamin B3 (Niacinamide & Niacin), 100% in-house sourcing of Beta Picoline (Key RM) from Speciality Chemicals

Speciality Chemicals

- 56% of our Pyridine & Picolines volume is used in-house for value-added products in Speciality Chemicals & for Vitamin B3
- CDMO business supported through vertical integration

Life Science Chemicals

- 41% of overall volume of Life Science Chemicals is in-house consumed by Speciality Chemicals segment

1. The above segmental sales figures are taken from Nine Months'FY22 Financials

Glorious Four Decades of Growth

Our Journey

10+ years experience in Vitamin B3

20+ years experience in Vitamin B4 & premixes

30+ years experience in Pyridine Chemistry & value added Speciality products

40+ years leadership in Life Science products (Acetyls)

We started in 1978 as VAM Organic Chemicals. Over the years we built Global-Scale capacities



1978

1981

1990

1998

1999

2000

2006-12

2013-18

2021

Started Acetic Anhydride (10 KTA), Acetic Acid (16 KTA), VAM (10KTA) plants at Gajraula, UP

Started Pyridine & Picolines plant (500 TPA), integrated with Aldehydes; Gajraula, UP

Acquired Nira facility in MH; with Acetic Acid (16.5 KTA), & VAM (10 KTA)

Commissioned additional capacity of Pyridine & Picolines plant (6 KTA), Gajraula

Acquired Vitamin B4 (Choline Chloride) facility (10 KTA) at Samlaya, GJ

2000: Started Multi Product Plant (72 TPA), Gajraula
Started Ethyl Acetate plant (20 KTA) in Nira, MH

2019: Started new Acetic Anhydride plant, Bharuch SEZ, GJ (50 KTA)
2018: Started Agro Intermediate plant (800 TPA), Bharuch SEZ
2017: Certified for Responsible Care (RC)
2015: Commissioned speciality MPP plant (120 TPA), Gajraula
2013: Commissioned world class Chlorinated Pyridine plant (24 KTA), Bharuch SEZ

2012: Commissioned additional Acetic Anhydride capacity (50 KTA), Nira
2011: Started state-of-the-art GMP Vitamin B3 plant at Bharuch SEZ (14 KTA)
2009: Augmented capacity of Pyridine & Picolines plant (60 KTA)
2008: Certified for Pre-mixes Quality System FAMI-QS for Vitamins
2007: Commissioned additional Acetic Anhydride capacity (17 KTA), Nira
2006: Invested in Speciality & Multipurpose plants, Gajraula

Demerger into new entity **Jubilant Ingrevia**

Company Snapshot

Leadership

- Globally # 1 in 14 Pyridine Derivatives
- Amongst top 2 Globally in (Pyridine + Beta)


- **Global Leadership in Niacinamide**; Globally among top 2 in **Vitamin B3** (Niacin & Niacinamide)

- **Leader** in India **Vitamin B4** (Choline Chloride)

Globally

- Amongst top 2 in **Acetic Anhydride**
- **Largest manufacturer of bio-based Acetaldehyde**

Revenue Segmentation: By Region (9M FY'22)



Total **1400+** customers

- Speciality Chemicals: **420**
- Nutrition & Health Solutions: **400**
- Life Science Chemicals: **600**


Total **165+** products

- Speciality Chemicals: **85**
- Nutrition & Health Solutions: **72**
- Life Science Chemicals: **8**

Sales in over **50** countries with **25%** of sales in regulated markets such as US, Europe, Japan - leading to sustainable revenue

Diverse Industry End-Use

9M FY'22 Revenue Split



(9M FY'22)

Revenue

₹ 3,654 Cr.

EBITDA

₹ 712 Cr. (19.5%)

Net Debt / EBITDA

rate of **0.24x**

Expertise in **35 Technology platforms** which include Acetyl, Pyridine/ Piperidine, Ketene/ Diketene, Halogenation & others (At large commercial scale)

Expertise in handling **multi-step chemistries** (Up to ~13 steps) At Commercial scale

Strong Corporate Governance, Quality regulatory & Compliance

In line with our Vision to double the Revenue by FY'26, we have **60+ Products** in Pipeline.

5 Global scale Manufacturing sites with **50** plants

Global workforce of **~2100** employees

Offices in **India, US, Europe, Japan & China**

Executive Leadership Team



Rajesh Srivastava
Chief Executive Officer &
Managing Director
*34 years of
industry experience*



Anil Khubchandani
President –
Speciality Chemicals
*29 years of industry
experience*



Chandan Singh
President –
Life Science Chemicals
*35 years of industry
experience*



Sumit Das
SVP – Nutrition &
Health Ingredients
*29 years of industry
experience*



Ashish Kumar Sinha
VP – Animal & Human
Nutrition & Health Solutions
*23 years of industry
experience*



Prakash Bisht
President &
Chief Financial Officer
*32 years of
industry experience*



Anant Pande
President &
Chief of Operations
*35 years of industry
experience*



Vinita Koul
SVP &
Head- HR
*25 years of industry
experience*



Prasad Joglekar
EVP & Head –
Supply Chain
*28 years of industry
experience*

Leadership team has an average 30 years of industry experience

Multi Location Manufacturing & Operation Excellence

Manufacturing Facilities



463 acres

Gajraula, Uttar Pradesh, India

Integrated facility for Speciality Chemicals & Life Science Chemicals



310 acres

Bharuch, Gujarat, India

Speciality Chemicals, Nutrition & Health Ingredients & Life Science Chemicals facility located in SEZ



144 acres

Nira, Maharashtra, India

Life Science Chemicals



109 acres

Samlaya, Gujarat, India

Animal Nutrition & Health Solutions



3.5 acres

Ambernath, Maharashtra, India

Speciality Chemicals

We operate 50 Plants across 5 sites in 3 states

We have enough land available at our existing sites for future expansions

Operation Highlights

Multi-Chemistry, Multi-Product and Process Condition handling expertise

Large capacities in **Continuous & Batch processes**

World Class GMP facility at Bharuch

Temp, Humidity & Differential Pressure Controlled Areas with ISO-8 (Class 100,000) Clean rooms

cGMP compliant Pilot Plant

20 – 1000L Reactors (Glass Assemblies, Cryogenic & Plug Flow reactors, Lyophilizer Autoclaves)

In-house Utilities

Captive Power Plant (Gajraula), Own Steam Generating Boilers, Chilled Water & Brine Unit

Ecologically Harmonized Practices

Incinerators, ETPs, Multi Effect Evaporators, Reverse Osmosis, Water Polishing Plants

Health & Safety:

benchmarking global performance by Chilworth Dekra- FY'07 & Chola MS- FY'21

Compliance: 3,800+ compliance items through 'EY' Conformity tool



End Usage Applications for Pharma, Agrochemicals & Nutraceuticals

<p>Off- Patented Pharma (APIs)</p>	<p>Therapeutic Category (Used in ~ 53 APIs)</p> <table border="0"> <tr> <td>Antipyretic</td> <td>Analgesic</td> <td>Antifibrosis</td> </tr> <tr> <td>Anti inflammatory</td> <td>Anticoagulant</td> <td>Anticonstipation</td> </tr> <tr> <td>Antibiotics</td> <td>Anti viral</td> <td>Anesthetic</td> </tr> <tr> <td>Antihistamine</td> <td>Antidiabetic</td> <td>Green Solvent</td> </tr> </table>	Antipyretic	Analgesic	Antifibrosis	Anti inflammatory	Anticoagulant	Anticonstipation	Antibiotics	Anti viral	Anesthetic	Antihistamine	Antidiabetic	Green Solvent	<p>Our Product Category (GMP & Non-GMP)</p> <table border="0"> <tr> <td>Pyridine, Picolines</td> <td>Amino Methyl Pyridines</td> <td>Chloro/ Bromo/ Fluoro Pyridines</td> </tr> <tr> <td>Amino Pyridines</td> <td>Hydroxy Methyl Pyridine</td> <td>Piperidine</td> </tr> <tr> <td>Acetic Anhydride</td> <td>Methyl Ethyl Pyridine</td> <td>Pyridine Aldehyde</td> </tr> <tr> <td>Azacyclonol</td> <td>Lutidines & Collidines</td> <td>Ethyl Acetate</td> </tr> </table>	Pyridine, Picolines	Amino Methyl Pyridines	Chloro/ Bromo/ Fluoro Pyridines	Amino Pyridines	Hydroxy Methyl Pyridine	Piperidine	Acetic Anhydride	Methyl Ethyl Pyridine	Pyridine Aldehyde	Azacyclonol	Lutidines & Collidines	Ethyl Acetate
Antipyretic	Analgesic	Antifibrosis																								
Anti inflammatory	Anticoagulant	Anticonstipation																								
Antibiotics	Anti viral	Anesthetic																								
Antihistamine	Antidiabetic	Green Solvent																								
Pyridine, Picolines	Amino Methyl Pyridines	Chloro/ Bromo/ Fluoro Pyridines																								
Amino Pyridines	Hydroxy Methyl Pyridine	Piperidine																								
Acetic Anhydride	Methyl Ethyl Pyridine	Pyridine Aldehyde																								
Azacyclonol	Lutidines & Collidines	Ethyl Acetate																								
<p>Patented Pharma (APIs)</p>	<p>Therapeutic Category (Used in ~ 12 APIs)</p> <table border="0"> <tr> <td>Antimalarial</td> <td>Antidiabetic</td> <td>Anti Cancer</td> </tr> <tr> <td>Antiretroviral</td> <td>Anticoagulant</td> <td>Breast Cancer</td> </tr> <tr> <td>Anti ulcerative</td> <td>Anti viral</td> <td>Anti fibrosis</td> </tr> </table>	Antimalarial	Antidiabetic	Anti Cancer	Antiretroviral	Anticoagulant	Breast Cancer	Anti ulcerative	Anti viral	Anti fibrosis	<p>Our Product Category (GMP & Non-GMP)</p> <table border="0"> <tr> <td>Dichloro pyridine</td> <td>Halo Azaindole</td> <td>AminoChloro & Methylpyridine</td> <td>Bromo Pyridine Fluoro Phenone</td> </tr> <tr> <td>Amino Pyrrole Derivative</td> <td>Hydroxy Methylpyridine</td> <td>Amino Piperidine derivative</td> <td>Sulphur Pyridine derivative</td> </tr> </table>	Dichloro pyridine	Halo Azaindole	AminoChloro & Methylpyridine	Bromo Pyridine Fluoro Phenone	Amino Pyrrole Derivative	Hydroxy Methylpyridine	Amino Piperidine derivative	Sulphur Pyridine derivative							
Antimalarial	Antidiabetic	Anti Cancer																								
Antiretroviral	Anticoagulant	Breast Cancer																								
Anti ulcerative	Anti viral	Anti fibrosis																								
Dichloro pyridine	Halo Azaindole	AminoChloro & Methylpyridine	Bromo Pyridine Fluoro Phenone																							
Amino Pyrrole Derivative	Hydroxy Methylpyridine	Amino Piperidine derivative	Sulphur Pyridine derivative																							
<p>Agrochemical & Antimicrobial</p>	<p>Used in ~ 23 Actives</p> <table border="0"> <tr> <td>Insecticide</td> <td>Fungicide</td> </tr> <tr> <td>Herbicide</td> <td>Antimicrobial</td> </tr> </table>	Insecticide	Fungicide	Herbicide	Antimicrobial	<table border="0"> <tr> <td>Pyridine, Picolines</td> <td>Acetic & Propionic Anhydride</td> </tr> <tr> <td>Amino Pyridines</td> <td>Cyano Pyridines</td> </tr> <tr> <td>Halo Pyridines</td> <td>Acetic & Propionic Anhydride</td> </tr> <tr> <td>Chloro Methyl Pyridines</td> <td>Pyrithiones Family</td> </tr> </table>	Pyridine, Picolines	Acetic & Propionic Anhydride	Amino Pyridines	Cyano Pyridines	Halo Pyridines	Acetic & Propionic Anhydride	Chloro Methyl Pyridines	Pyrithiones Family												
Insecticide	Fungicide																									
Herbicide	Antimicrobial																									
Pyridine, Picolines	Acetic & Propionic Anhydride																									
Amino Pyridines	Cyano Pyridines																									
Halo Pyridines	Acetic & Propionic Anhydride																									
Chloro Methyl Pyridines	Pyrithiones Family																									
<p>Nutraceuticals</p>	<p>Nutraceutical ingredients:</p> <p>Animal Health Solutions : Liver protection, Better Meat quality, Anti-stress, Egg quality enhancer, Gut health solutions, Immunity Enhancer</p>	<p>Niacin/ Niacinamide (Vitamin B3), Choline Chloride (Vitamin B4), RPS, Picolinates & Hexanicotinate</p> <p>Various Nutritional premixes</p>																								



Industry Overview: Presence in Large & Growing Markets¹



Speciality Chemicals





Nutrition & Health Solution*



* Sum of Vit Feed Supplements+ Functional Food Ingredients + Nutraceuticals + Pet Food + Feed Additives

Life Science Chemicals



1) Source: M & M Report 2020

2) Merchant Market; IHS Report

3) Frost & Sullivan Report, Benchmark ICIS Prices



Financial Highlights: Q3 FY'22 & 9M FY'22

Chairmen's Message on Q3 Financial Results



Mr. Shyam S Bhartia
Chairman



Mr. Hari S Bhartia
Co-Chairman

"We are pleased to announce that in Q3'FY22 we continued to witness significant growth in our Revenue & EBITDA. We are also delighted to declared an interim dividend of Rs. 2.5 per equity share of Rs 1 each of the company amounting to Rs 39.8 Cr.

In our Specialty Chemicals segment we maintained strong growth across the products led by growing demand from Pharmaceutical, and Nutrition customers. In Nutrition & Health Solution the demand of Vitamin B3 improved and we placed higher volumes with improved realizations. In Life Science Chemical Segment, we continued the strong performance with healthy demand in domestic as well as in EU market.

Our business team worked closely with customers and ensured that most of the increase in input cost is passed on and our supply chain team ensured the uninterrupted supplies and timely deliveries.

We are pleased to inform, that in DJSI (Dow Jones Sustainability Index) Environmental Social & Governance (ESG) assessment, we scored 81 percentile in the global chemical industry and have been ranked among the top 20% chemical companies globally and amongst the Top 3 chemical companies in India.

We remain excited with the growth opportunities in our businesses and are fully committed to realize them. Our strong new product pipeline developed by our in-house R&D, our technical expertise into various chemistry platforms and long-standing relationship with global Pharmaceutical & Agrochemical customers is a strong enabler in our growth journey . With our growth capex plans shaping up we remain in course of doubling the revenue by FY'26 from the base of FY'21."

Financial Highlights¹ : Key Financial Parameters

Highlights	Sales	EBITDA	EBITDA (%)	PAT	PAT (%)	EPS
Highlights Q3'FY22	₹ 1,286 Cr.	₹ 222 Cr.	17.3%	₹ 129 Cr.	10.0%	₹ 8.1
	↑ 44% YoY	↑ 42% YoY	↓ (29) bps	↑ 42% YoY	↓ (15) bps	↑ 42% YoY
Highlights Q3'FY21²	₹ 893 Cr.	₹ 157 Cr.	17.5%	₹ 91 Cr.	10.2%	₹ 5.7
Highlights 9M'FY22	₹ 3,654 Cr.	₹ 712 Cr.	19.5%	₹ 408 Cr.	11.2%	₹ 25.7
	↑ 51% YoY	↑ 68% YoY	↑ 191 bps	↑ 85% YoY	↑ 202 bps	↑ 85% YoY
Highlights 9M'FY21²	₹ 2,413 Cr.	₹ 424 Cr.	17.6%	₹ 221 Cr.	9.1%	₹ 13.9

1. All figures are in Rs Crore unless otherwise stated

2. - Q3 & 9M'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis

- EPS for previous periods has been computed on combined profits assuming existence of share capital for full period.

Jubilant Ingrevia – Q3 FY'22 Financial Results Summary




Particulars ¹	Q3'FY21 ²	Q3'FY22	YoY (%)
Revenue			
Speciality Chemicals	285	349	22%
Nutrition & Health Solutions	157	216	37%
Life Science Chemicals	451	722	60%
Total Revenue from Operations	893	1,286	44%
Reported EBITDA	157	222	42%
Speciality Chemicals	59	76	28%
Nutrition & Health Solutions	28	53	87%
Life Science Chemicals	68	100	48%
Unallocated Corporate (Expenses)/Income	1	-7	-
PAT	91	129	42%
EPS	5.7	8.1	42%
Reported EBITDA Margins	17.5%	17.3%	
Speciality Chemicals	20.8%	21.8%	
Nutrition & Health Solutions	17.9%	24.4%	
Life Science Chemicals	15.0%	13.9%	
Net Margin	10.2%	10.0%	


FINANCIAL HIGHLIGHTS

- Revenue grew by 44% on YoY basis, driven by growth across product segments.
- Revenue from Pharma, Nutrition and Agro end use increased significantly.
- Speciality Chemicals revenue grew by 22% YoY driven by volume growth across products and passing-on of higher input costs.
- Nutrition and Health Solutions revenue grew by 37% YoY driven by higher volumes and improved price realisation.
- Life Sciences Chemical revenue grew by 60% YoY, driven by higher prices on account of favorable market conditions.
- EBITDA at Rs 222 Crore, grew by 42%, on account of strong performance of all three product segments.
- PAT grew by 42% YoY driven by growth in EBITDA, added by reduction in finance cost through reduction in Gross debt and optimization of Interest rates.
- ROCE in 9M'FY22 improved to 31.1% as against 20.2% in FY21.
- ROE in 9M'FY22 stood at 25.2% as against 16.4% in FY21.

Q3'FY22 Geographical Revenue Split



Q3'FY22 Industry End-Use Split



- All figures are in Rs Crore unless otherwise stated
- Q3 & 9M'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
- EPS for previous periods has been computed on combined profits assuming existence of share capital for full period.
- ROCE & ROE for 9M'FY22 is calculated on the basis of extrapolation of Nine months performance during FY22.


Jubilant Ingrevia – 9M FY'22 Financial Results Summary

Particulars ¹	9M'FY21 ²	9M'FY22	YoY (%)
Revenue			
Speciality Chemicals	794	949	19%
Nutrition & Health Solutions	431	562	30%
Life Science Chemicals	1,189	2,143	80%
Total Revenue from Operations	2,413	3,654	51%
Reported EBITDA	424	712	68%
Speciality Chemicals	199	231	16%
Nutrition & Health Solutions	88	114	30%
Life Science Chemicals	131	387	195%
Unallocated Corporate (Expenses)/Income	6	-21	-
PAT	221	408	85%
EPS	13.9	25.7	85%
Reported EBITDA Margins	17.6%	19.5%	
Speciality Chemicals	25.1%	24.4%	
Nutrition & Health Solutions	20.4%	20.3%	
Life Science Chemicals	11.0%	18.1%	
Net Margin	9.1%	11.2%	


FINANCIAL HIGHLIGHTS

- Revenue grew by 51% on YoY basis, driven by growth across product segments.
- Speciality Chemicals revenue grew by 19% YoY driven by volume growth across product .
- Nutrition and Health Solutions revenue grew by 30% YoY driven by higher volumes and as well as higher prices.
- Life Sciences Chemical revenue grew by 80% YoY, driven by higher prices on account of improved price realization on account of favorable market conditions.
- EBITDA at Rs 712 Crore, grew by 68% on account of strong performance of all the three product segments and favorable market conditions in Life Sciences segment.
- PAT grew by 85% YoY driven by growth in EBITDA, aided by reduction in finance cost on account of reduction in Debt and optimization of Interest rates.
- ROCE in 9M'FY22 improved to 31.1% against 20.2% in FY21
- ROE in 9M'FY22 stood at 25.2% as against 16.4% in FY21.

9M'FY22 Geographical Revenue Split



9M'FY22 Industry End-Use Split



- All figures are in Rs Crore unless otherwise stated
- Q3 & 9M'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
- EPS has been computed on combined profits assuming existence of share capital for full period.
- ROCE & ROE for 9M'FY22 is calculated on the basis of extrapolation of nine months performance during FY22.


Debt Profile – As on 31st December, 2021

Particulars ¹	31-Mar-21	30-Jun-21	30-Sep-21	31-Dec-21
Long Term Borrowings	548	227	218	100
Short Term Borrowings	-	230	45	184
Total Gross Debt	548	457	263	284
Cash & Equivalent	117	70	70	54
Total Net Debt	431	386	193	230
QoQ change		-10%	-50%	19%


- Gross Debt reduction by Rs 263 Crore and Net Debt reduction by Rs 201 Crore from 31st March 2021.
- Net Debt to EBITDA in Q3'FY22 stands at 0.24 times, from the earlier level of 0.69 times as on 31st March, 2021.
- Closing blended interest rate in Q3'FY22 was 5.25%, as against 7.01 % in Q4'FY21

Balance Sheet – Key Parameters/Ratios (Pro-Forma²)


Return On Capital Employed (RoCE)




Return on Equity



Asset / Turnover and Return On Asset (RoA)



Net Working Capital




[#] The Net Working Capital %age to Turnover & No of days on the basis of Q3'FY22 Annualized Turnover are 16.5% & 60 Days respectively

● % to Annualized Turnover ○ No of Days of Working Capital

- Balance Sheet Ratios strengthened on improved performance:
 - RoCE improved significantly to 31.1% in Nine Months'FY22
 - RoE improved at 25.2% in Nine Months'FY22
 - Asset to Turnover increased to 2.8x in Nine Months'FY22
- Increase in Net Working Capital is driven by higher Raw Material cost and Sale price leading to higher value of inventory and debtors and 'Make Vs Buy'(Import) of ethanol due to higher import prices.


- All figures are in Rs Crore unless otherwise stated
- FY21 is calculated from 10 month of discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months of Jubilant Ingrevia Limited
- 9M'FY22 is calculated on the basis of extrapolation of nine months performance during FY22

BUSINESS SEGMENTS OVERVIEW



Speciality Chemicals – Segment Snapshot


<p>85 Products (Pyridines & Picolines, Cyanopyridines, Piperidines, Aminopyridines, Lutidines)</p>	<p>Amongst top 2 Globally in (Pyridine + Beta), - Globally #1 in 14 Pyridine Derivatives</p>	<p>Globally lowest cost producer of Pyridine offering significant long term advantage</p>
<p>Market size (In current Jubilant Products): \$ 1240 Mn Jubilant's Market Share: ~13%</p>	<p>25 plants across 3 Sites</p>	<p>Products are REACH, HALAL & KOSHER certified</p>



FY'21 Capacity Utilisation: 74%

<p><u>Capacity Growth in FY'22 over FY'21:</u> Debottlenecking: 1% New Capacity addn: 14%</p>	<p><u>Capacity Growth in FY'23 over FY'21:</u> Debottlenecking: 13% New Capacity addn: 18%</p>
<p>Expected Utilisation FY'22: 91%</p>	<p>Expected Utilisation FY'23: 92%</p>

<p><u>Capacity Growth in FY'24 over FY'21:</u> Debottlenecking: 14% New Capacity addn: 43%</p>
<p>Expected Utilisation FY'24: 93%</p>



- “Partner of Choice” to ~420 global customers
- Serving 15 of top 20 Global Pharma & 7 of top 10 Global Agrochemical companies
- International reach through offices in US, Europe, Japan & China
- Around 40% export in regulated markets leading to sustainable revenue

Key Investment Projects

- 1 Diketene & Derivatives (Phase-1&2) (Q4 FY'22 & Q2 FY'24)
- 2 CDMO GMP & Non – GMP Facility (Q2 FY'23)
- 3 MPP - Insecticides/ Fungicides/ Herbicide (Q4 FY'23)


Investment of ~INR 550 Cr. by FY'24

In line with our Vision to double the Revenue by FY'26, we have **36 Products** in Pipeline.


Speciality Chemicals Segment Highlights – Q3 FY'22

Particulars ¹	Q3'FY21 ²	Q3'FY22	YoY (%)
Revenue	285	349	22%
Reported EBITDA	59	76	28%
Reported EBITDA Margin (%)	20.8%	21.8%	

Q3'FY22 Geographical Revenue Split



Q3'FY22 Industry End-Use Split



*Industrial include Paints & Coatings, Print & Packaging, Solvents etc.
 **Consumer include Personal Care, Fragrances etc.

1. All figures are in Rs Crore unless otherwise stated
 2. - Q3 & 9M'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
 3. Specialty Chemicals Segment comprises Specialty Ingredients, Fine Chemicals, Crop Protection chemicals & CDMO

FINANCIAL HIGHLIGHTS

- Specialty Chemicals revenue grew by 22% on YoY basis driven by higher volume across product segments
- Pharma Sales share to total revenue grew to 52% from 47% earlier
- Revenue from Nutrition and Consumer end use also improved significantly during the quarter

EBITDA:

- EBITDA increased by 28% on YoY basis, and EBITDA Margin increased at 21.8% vs 20.8% in Q3'FY21, mainly due to higher volumes and improved realization despite higher input costs.

BUSINESS HIGHLIGHTS

- We witnessed positive traction of demand from both domestic as well as international customers
- Working with customers our business team ensured passing on most of the input cost increase.
- Global logistic challenges continued, however our supply chain team ensured on-time deliveries to customer leveraging our large volume and long-standing relationship with shipping and transport companies.


Speciality Chemicals Segment Highlights – 9M FY'22

Particulars ¹	9M'FY21 ²	9M'FY22	YoY (%)
Revenue	794	949	19%
Reported EBITDA	199	231	16%
Reported EBITDA Margin (%)	25.1%	24.4%	


FINANCIAL HIGHLIGHTS

- Specialty Chemicals revenue grew by 19% on YoY basis driven by higher volume across product.
- Domestic sales revenue grew significantly, percentage share to total revenue increased to 38% from 25%
- Sales in North American region increased by 60% on YoY basis.
- Sales from pharma and Nutrition end-use segment grew significantly on YoY basis
- Consumer as percentage share to total revenue increased to 10% from 8%
- EBITDA:**
- EBITDA grew by 16% YoY. EBITDA Margin were at 24.4% vs 25.1% in 9M'FY21, due to higher raw material prices and increase in other input costs.

9M'FY22 Geographical Revenue Split



9M'FY22 Industry End-Use Split




*Industrial include Paints & Coatings, Print & Packaging, Solvents etc.
 **Consumer include Personal Care, Fragrances etc.

1. All figures are in Rs Crore unless otherwise stated
 2. - Q3 & 9M'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
 3. Specialty Chemicals Segment comprises Specialty Ingredients, Fine Chemicals, Crop Protection Chemicals & CDMO

Nutrition & Health Solutions – Segment Snapshot

<p>5 Nutrition Ingredients & 18+ branded solutions (For Animal Health)</p>	<p>Global top 2 in Vitamin B3 Domestic leader in Vitamin B4 (Feed)</p>	<p>100% in-house sourcing of Beta Picoline (Key RM) for Vitamin B3 via green route</p>
<p>20% Global market share in Vitamin B3 60% domestic share in Vitamin B4</p>	<p>5 Plants across 2 Sites</p>	<p>WHO GMP, FSSAI, HALAL, KOSHER and FAMI-QS certified</p>



FY'21 Capacity Utilisation: 70%

<p><u>Capacity growth in FY'22 over FY'21:</u></p> <p>Debottlenecking: 0%</p> <p>New Capacity addn: 0%</p>	<p><u>Capacity growth in FY'23 over FY'21:</u></p> <p>Debottlenecking: 0%</p> <p>New Capacity addn: 32%</p>
<p>Expected Utilisation FY'22: 89%</p>	<p>Expected Utilisation FY'23: 83%</p>
<p><u>Capacity growth in FY'24 over FY'21:</u></p> <p>Debottlenecking: 2%</p> <p>New Capacity addn: 48%</p>	
<p>Expected Utilisation FY'24: 83%</p>	

Animal Nutrition & Health Solutions Brands

Poultry	Dairy	Aqua
Liver Protection Solutions: ANICHOL PhytoShield	Milk Enhancer Solutions: ANICHOL-RP , NUTRA PLUS	Gut Health Solutions: GLYMIN AQUA , JUBIMIN PLUS-AQUA
Better Meat Quality: EnCroMix	Anti-Stress Solutions: EnCroMix	Feed Efficiency Solutions: Acifeed Aqua
Anti-Stress Solutions: CsmoBETAINE , EnCroMix	Milk Quality Solutions: JUBILYS RP , JUBIMETH RP	Feed Quality Solutions: Acifeed Aqua
Egg Quality Enhancer: "Egghancer"	Transition Health Solutions: NIACON RP	
Feed Quality Solutions: ToxiCOP , Jubacid		
Feed Efficiency Solutions: JubiDOL		
Gut Health Solutions: ButyMAX		
Immunity Enhancer: Hi-Pro-Min , NIACON , Hi-Pro-Min		
Non - AGP Solutions: GROPLUS		

Niacinamide End Use Applications

"Partner of Choice" to ~400 global customers and has established strong distribution network

Globally, we serve **90+** customers in Cosmetics, **55+** Customers in Dietary supplements & **20+** Customers for Energy Drinks and Breakfast Cereals.

Strategic partnership for the Human Nutrition line of products

More than half of the exports in regulated markets leading to sustainable revenue

Key Investment Projects

- Nutrition Premix Plant expansion** for Animal & Human Nutrition (Q1 FY'24)
- Facility upgrade for Pharma Grade Vitamin B3** (Q3 FY'24)
- Niacinamide Capacity Expansion** (Q3 FY'23)


Investment of ~INR 100 Cr. by FY'24

In line with our Vision to double the revenue by FY'26, we have **18 Products** in Pipeline.


Nutrition & Health Solutions Segment Highlights – Q3 FY'22

Particulars ¹	Q3'FY21 ²	Q3'FY22	YoY (%)
Revenue	157	216	37%
Reported EBITDA	28	53	87%
Reported EBITDA Margin (%)	17.9%	24.4%	

Q3'FY22 Geographical Revenue Split



Q3'FY22 Industry End-Use Split



FINANCIAL HIGHLIGHTS

- Nutrition and Health Solutions revenue grew by 37% on YoY basis.
- Growth of Vitamin Business was driven by higher volumes and improved prices .
- Revenue share from EU increased to 36% as against 20% last year and share from North America increased to 21% from 11% earlier
- Food and cosmetics volumes grew significantly

EBITDA

- EBITDA grew by 87% on YoY basis. EBITDA Margin improved at 24.4% vs 17.9% in Q3'FY21,
- EBITDA margin was higher by 6.5% on account of higher volumes and improved price realizations.

BUSINESS HIGHLIGHTS

- Demand of Niacinamide (Vit B3) during the quarter has been strong. We could realize higher volumes as well as better prices.
- We continue to focus on improving our market share in niche segments like Food & Cosmetics and to enhance our market share in North America, EU and Japan markets.
- Animal Nutrition business continues making efforts to increase share of speciality premixes through various initiatives

1. All figures are in Rs Crore unless otherwise stated
2. - Q3 & 9M'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
3. Nutrition & Health Solutions Segment comprises, Nutrition & Health Ingredients, Animal Nutrition & Health Solutions, Human Nutrition & Health Solution


Nutrition & Health Solutions Segment Highlights – 9M FY'22

Particulars ¹	9M'FY21 ²	9M'FY22	YoY (%)
Revenue	431	562	30%
Reported EBITDA	88	114	30%
Reported EBITDA Margin (%)	20.4%	20.3%	


FINANCIAL HIGHLIGHTS

- Nutrition and Health Solutions revenue grew by 30% on YoY basis.
 - Growth of Vitamin Business was driven by higher volumes and improved prices .
 - Animal Nutrition and Health solution business also improved volumes and realization YOY.
- Consumption in EU and North America has gone up significantly.
- Feed and Food demand has gone up on YoY basis in higher double digit

9M'FY22 Geographical Revenue Split



9M'FY22 Industry End-Use Split



EBITDA

- EBITDA grew by 30% on YoY basis. EBITDA Margin stood at 20.3% , EBITDA margin remained flat mainly on account of continuing increase in input costs and along with discontinuation of export benefit (MEIS).

1. All figures are in Rs Crore unless otherwise stated
 2. - Q3 & 9M'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
 3. Nutrition & Health Solutions Segment comprises, Nutrition & Health Ingredients, Animal Nutrition & Health Solutions, Human Nutrition & Health Solution

Life Sciences Chemicals – Segment Snapshot

8 Products

(Acetic Anhydride, Ethyl Acetate, Propionic Anhydride, Aldehydes, Speciality Alcohol, Anhydrous Alcohol)

Acetic Anhydride:
Globally No. 2 in Merchant Mkt
No.1 in India
Expected to be **Global leader** by FY'24


Entered Value added derivative **Propionic Anhydride**
Replace all imports in India;
Also enter international Mkt

Ethyl Acetate:
Among top 2 in Domestic market

20 plants across **3 Sites**
(Multi-location, Multi-plant advantage)

Products are REACH, HALAL & KOSHER certified

Region wise Revenue Segmentation For Segment (9M FY'22)



FY'21 Capacity Utilisation: 69%

Capacity growth in FY'22 over FY'21
Debottlenecking: 1%
New Capacity addn: 4%

Capacity growth in FY'23 over FY'21
Debottlenecking: 7%
New Capacity addn: 15%

Expected Utilisation FY'22: 83%


Expected Utilisation FY'23: 90%

Capacity growth in FY'24 over FY'21
Debottlenecking: 7%
New Capacity addn: 15%

Expected Utilisation FY'24: 90%.

Diverse Industry End-Use

9M FY'22 End Use Split



“Partner of Choice” to ~600 global customers
European Union is the major deficit market: nearly **90%** import dependent for Acetic Anhydride; nearly **70%** import dependent for Ethyl Acetate.

India Pharma and Agro applications are estimated to witness strong growth, mainly driven by Paracetamol, Acephate and Ibuprofen.

Shift of manufacturing from China to India will encourage growth in various industrial applications in India.

Key Investment Projects

1 Food grade Acetic Acid plant (Q1 FY'23)

2 Acetic Anhydride capacity expansion (Q4 FY'23)


Investment of ~ **INR 250 Cr.** by FY'24

In line with our Vision to double the Revenue by FY'26, we have **7 Products** in Pipeline.


Life Science Chemicals Segment Highlights – Q3 FY'22

Particulars ¹	Q3'FY21 ²	Q3'FY22	YoY (%)
Revenue	451	722	60%
Reported EBITDA	68	100	48%
Reported EBITDA Margin (%)	15.0%	13.9%	

Q3'FY22 Geographical Revenue Split



Q3'FY22 Industry End-Use Split



FINANCIAL HIGHLIGHTS

- Life Sciences Chemicals revenue grew by 60% on YoY basis
 - Life Sciences Chemical revenue growth was driven by higher prices of Ethyl Acetate and Acetic Anhydride. Prices improvement was mainly on account of favorable market condition.
 - Overall Domestic sales for domestic consumption as well as for international consumption both have gone up significantly on YoY basis

EBITDA

- EBITDA grew by 48% YOY. EBITDA Margin stood at 13.9%. Growth in EBITDA margin was driven by
- Improved product contribution driven by favorable market.

BUSINESS HIGHLIGHTS

- We started the quarter with high prices of Acetic Acid, which started softening during the end of quarter
- Maintained domestic market leadership for Acetic Anhydride and increased market presence in EU, Americas and Rest of the world.
- Our value-added product Propionic Anhydride, witnessed strong demand during the end of the quarter.

- All figures are in Rs Crore unless otherwise stated
- Q3 & 9M'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
- Life Science Chemicals Segment comprises, Life Science Ingredients and Speciality Ethanol

Life Science Chemicals Segment Highlights – 9M FY'22

Particulars ¹	9M'FY21 ²	9M'FY22	YoY (%)
Revenue	1,189	2,143	80%
Reported EBITDA	131	387	195%
Reported EBITDA Margin (%)	11.0%	18.1%	


FINANCIAL HIGHLIGHTS

- Life Sciences Chemicals revenue grew by 80% on YoY basis
 - Life Sciences Chemical revenue growth was driven by higher prices and volume growth in Acetic Anhydride.
 - Prices improvement was mainly on account of favorable market condition and improved realization of Ethyl Acetate
 - Revenue from domestic sales for domestic consumption and domestic sales for exports both have gone up significantly on YoY basis.


EBITDA

- EBITDA grew by 195%. Margin stood at 18.1%. Growth in EBITDA margin was driven by
 - Improved product contribution driven by favorable market conditions of Acetic Anhydride.
 - Improved pricing of Ethyl Acetate also contributed to margin expansion.

9M'FY22 Geographical Revenue Split



9M'FY22 Industry End-Use Split



1. All figures are in Rs Crore unless otherwise stated
 2. - Q3 & 9M'FY21 is derived from reported discontinued operation results of LSI segment of Jubilant Pharmova Limited on Pro-forma basis.
 3. Life Science Chemicals Segment comprises, Life Science Ingredients and Speciality Ethanol



Future Outlook & Investments

- We expect demand of most of our Products to remain strong.
- Our Diketene plant is under commissioning now, and we expect to start our commercial production during the current quarter.
- Our committed investment worth Rs. 450 Crore for key growth capex is progressing well . At peak capacity these investments are expected to generate additional annual revenue of Rs. 900-1,000 Crore at prevailing prices
 - Food Grade Acetic Acid. (Expected to be in operation during the quarter April to June 2022)
 - CDMO GMP Facility at Bharuch. (Expected to be in operation during the quarter July to September 2022)
 - Three Multi-Purpose plants of Speciality Chemicals. (Expected to be in operation during the quarter July to September 2022)
 - Acetic Anhydride Plant. (Expected to be in operation during the quarter January to March 2023)
 - Agro Actives Phase-1. (Expected to be in operation during the quarter January to March 2023)
- Our expected capex cash outflow for the year is expected to be in the range of Rs 300 crore.

Overall Expansion Plan: Jubilant Ingrevia



Plan to double the Revenue by FY'26 from the base of FY'21. Key Projects starting during next 3 years (Quarter in which production is starting)

FY'22

- Diketene investment (Phase 1)**– Moving up the value chain of Ketene, Growing demand & Exit of the old leading producer **(Q4 FY'22)**

FY'23

- Food Grade Acetic Acid**– Green Acetic Acid for food applications **(Q1 FY'23)**
- CDMO (GMP) Multipurpose plant**– For Pharma intermediates **(Q2 FY'23)**
- CDMO (Non-GMP) Two Multipurpose plant** for Pharma & Agro intermediates **(Q2 FY'23)**
- MPP Agro Active plant** – Moving up the value chain of Crop Protection actives & Growing customer demand **(Q4 FY'23)**
- Acetic Anhydride capacity expansion** – Growing demand & Geographic expansion **(Q4 FY'23)**



- Animal & Human Nutrition Premix plant** – Moving up the value chain from Ingredients to Premixes **(Q1 FY'24)**
- Pharma Grade Vitamin B3 (USFDA, EU CEP)** – For niche application in Pharmaceuticals **(Q3 FY'24)**

FY'24

- Niacinamide capacity expansion** – Geographic Expansion and Moving forward for value added end uses **(Q3 FY'23)**

- Diketene investment (Phase 2)**– Moving up the value chain of Ketene, Growing demand & Exit of the old leading producer **(Q2 FY'24)**


Capacity Build Up for Growth



Rationale for Investment

	Proposed Investment	Rationale for Investment
Speciality Chemicals	<p><u>New facility for launch of 6 Diketene derivatives. Subsequently, add 8 value-added Diketene derivatives</u></p> <p><u>CDMO Expansion</u> - Invest in GMP & Non-GMP multi-product facility for Pharma & Crop Protection customers</p> <p><u>Agro-active: New world class multi-product facilities for pesticides.</u></p> <p style="background-color: #007060; color: white; text-align: center; padding: 5px;">Indicative Investment¹ of about Rs. 550 Cr. in 3 years</p>	<p>Forward integration of our Ketene capability and growing demand of Diketene derivatives globally as well as Import replacement in India.</p> <p>Growing demand of global customers and their de-risking strategy from China</p> <p>Global agro customers are approaching to de-risk supply chain on agro-active. Moving up the value-chain from our existing products to produce agro-active</p>
Nutrition & Health Solution*	<ul style="list-style-type: none"> • Expand Vitamin B3 capacity by ~20% from current 13,000 MT/Year and launch various value-added grades of Vitamin B3 • Upgrade our facility to US DMF & European CEP compliant and enter regulated pharma market of Niacinamide <p>Enhance our portfolio with value-added premixes and investment for premix plant expansion</p> <p style="background-color: #007060; color: white; text-align: center; padding: 5px;">Indicative Investment¹ of about Rs.100 Cr. in 3 years</p>	<p>We are the lowest cost producer and fully backward integrated Expanding geography and adding value-added Vitamin B3 in Pharma, cosmetic etc.</p> <p>Growing demand of Speciality animal nutrition products from our customers</p>
Life Science Chemicals	<p>Invest in another Acetic Anhydride facility to increase capacity by ~35% and further strengthen global leadership</p> <p style="background-color: #007060; color: white; text-align: center; padding: 5px;">Indicative Investment¹ of About Rs 250 Cr. in 3 years</p>	<p>Growing demand No new facility globally Customers are exploring to shift from high cost to low cost countries</p>

¹Indicative plans – subject to the approval from Board of Directors



QUALITY














**BUSINESS
EXCELLENCE**



SUSTAINABILITY

Jubilant Ingrevia: Global Accreditation



Select Certifications	Gajraula	Bharuch	Nira	Samlaya	Ambernath
 Responsible Care RC 14001:2015	✓	✓	✓		
 ISO 9001:2015	✓	✓	✓	✓	✓
 ISO 22000:2005	✓	✓	✓		
 ISO 14001:2015	✓	✓	✓	✓	
 ISO 45001:2018	✓	✓	✓	✓	
 FSSAI	✓	✓	✓	✓	
 FAMI-QS		✓		✓	
 HALAL KOSHER	✓	✓	✓		
 GMP Quality Certification	State FDA GMP	State FDA GMP & WHO GMP			
 ISO 50001	✓	✓			
 TOGETHER FOR SUSTAINABILITY		✓ (FY'19)	✓ (FY'20)		
ISO/IEC 17025- NABL	✓	✓			



Certification for Jubilant Life Sciences Ltd.: FY'20 (Gold Category)

Business Excellence and Digital Transformation

Belt Competencies (FY'21)

Black Belts: 08

Green Belts: 98

Yellow Belts: 141

Business Excellence (17+ years experience)

Design Excellence

Strengthen Development Capability by exploring complete design space and target Right First Time

Operational Excellence

- Removing process inefficiencies
- improve cost effectiveness
- Addressing process variation
- Improve asset utilization

Customer Excellence

- Effective time & cost management for customer's NPD projects
- Analytics for accurate forecasting

Tools & Processes

Theory of Constraints

Quality by Design

Mission Directed Team

Balanced Scorecard

Six Sigma

Lean

TPM

Process Engineering

CRM

Analytics

Stage Gate deployment

Customer Dashboard

Digital Transformation

- Our journey started in 2018 with an objective to **improve**
 - Operational efficiency
 - Business & Supply chain processes
 - customer experience and engagement
- Every project we consider is based on the individual business case



Sustainability

- Energy Demand Forecasting
- Electronic Production Management
- Demand & Production Planning
- Digitally Accelerated Contract Manufacturing



Efficiency Improvement

- Upgradation & Security enhancement of ERP
- Process Automation
- Employee Collaboration
- Digital Factory



Customer Engagement

- Customer Experience
- Digital Sales through Salesforce Automation & Project & Workflow Management Platforms

Established
in 2007

Mission: To develop multi-stakeholder sustainable models to bring about 'social change' involving knowledge generation & sharing, experiential learning & entrepreneurial ecosystem



A sister organization of World Economic Forum in Partnership with Jubilant Bhartia Foundation

Education



- 50,000 students in 275 govt. primary schools
- Developed digital platform "Jubilant Education System"
- Introduced Digital Classes in Government schools

Improving Health



- Jubilant Aarogya - Affordable healthcare services
- Swasthya Prahari – Conduction Growth Monitoring of 10,000+ children from 0 to 5 yrs of age and BCC to decrease malnutrition

Escalating Employability



- Skill Development program for training 2500 youth every year.
- Promote Self sustainable Micro Enterprise

Social Entrepreneurship



- JBF with the Schwab Foundation recognize & award exceptional individuals in Social Business
- Providing business to social enterprises

FACE- Centre for Excellence




An initiative between CII & Jubilant Bhartia to improve productivity of agriculture and increase farmer income



Sustainability Journey

Our Sustainability Journey



SDG: Key Achievements

37% Reduction in Specific Water Consumption wrt FY'13

27% Reduction in Specific Greenhouse Gas Emissions wrt FY'13

25% Reduction in Specific Energy Consumption wrt FY'13

44964 Training man-days were imparted from FY'14


ESG Assessment



First time participated in S&P DJSI Assessment:

- Achieved **81 %ile** in the Global Chemical Industry
- Among the **top 20% companies globally**
- Among **top 3 Indian Chemical companies** in ESG score

OH&S Journey



S&P Global for DJSI 2021: **Top 3 Indian Chemical companies in ESG**

2018 **FICCI Safety Award**
FICCI Water Award

2016 **FICCI Chemicals & Petrochemicals Awards**

ecovadis
Gold Rating



2019 **National Energy Conservation Award**

Logistics & Supply Chain Awards 2019

2016 **CII Excellence in Energy Award**

Our Vision, Values, Promise and Philosophy

OUR VISION

- To acquire and maintain global leadership position in chosen areas of businesses
- To continuously create new opportunities for growth in our strategic businesses
- To be among the top 10 most admired companies to work for
- To continuously achieve a return on invested capital of at least 10 points higher than the cost of capital

OUR PROMISE

Caring, Sharing, Growing

We will, with utmost care for the environment and society, continue to enhance value for our customers by providing innovative products and economically efficient solutions; and for our stakeholders through growth, cost effectiveness and wise investment of resources

OUR VALUES



OUR PHILOSOPHY



Caring



Sharing



Growing

For Investors:

Pavleen Taneja

Ph: +91 120 436 1021

E-mail: pavleen.taneja@jubl.com

For Media:

Sudhakar Safaya

Ph: +91 120 436 1034

E-mail: sudhakar.safaya@jubl.com

Siddharth Rangnekar

CDR India

Ph: +91 22 6645 1209

E-mail: siddharth@cdr-india.com

Clayton Dsouza

Madison Public Relations

E-mail: clayton.dsouza@madisonpr.in

Phone number: +91 9930011602

Thank you for your time

Jubilant Ingrevia Limited

1A, Sector-16A, Noida - 201 301, Uttar Pradesh, India

Email: support@jubl.com | www.jubilantingrevia.com

Appendix I: Income Statement – Q3 & 9M FY'22

Particulars ¹	Q3'FY21 ²	Q3'FY22	YoY (%)	9M'FY21 ²	9M'FY22	YoY (%)
Total Revenue from Operations	893	1,286	44%	2,413	3,654	51%
Speciality Chemicals	285	349	22%	794	949	19%
Nutrition & Health Solutions	157	216	37%	431	562	30%
Life Science Chemicals	451	722	60%	1,189	2,143	80%
Total Expenditure	740	1,074	45%	2,001	2964	48%
Other Income	4	9	154%	12	22	
Segment EBITDA						
Speciality Chemicals	59	76	28%	199	231	16%
Nutrition & Health Solutions	28	53	87%	88	114	30%
Life Science Chemicals	68	100	48%	131	387	195%
Unallocated Corporate (Expenses)/Income	1	-7	(585%)	6	-21	(435%)
Reported EBITDA	157	222	42%	424	712	68%
Depreciation and Amortization	31	30	(2%)	92	92	0%
Finance Cost	13	5	(63%)	59	25	(58%)
Profit before Tax (After Exceptional Items)	113	187	66%	273	594	118%
Tax Expenses (Net)	22	58	167%	52	186	256%
PAT	91	129	42%	221	408	85%
EPS - Face Value Re. 1 (Rs.)	5.7	8.1	42%	13.9	25.7	85%
Segment EBITDA Margins						
Speciality Chemicals	20.8%	21.8%		25.1%	24.4%	
Nutrition & Health Solutions	17.9%	24.4%		20.4%	20.3%	
Life Science Chemicals	15.0%	13.9%		11.0%	18.1%	
Reported EBITDA Margin	17.5%	17.3%		17.6%	19.5%	
Net Margin	10.2%	10.0%		9.1%	11.2%	

1. All figures are in Rs Crore unless otherwise stated

2. - Q3 & 9M'FY21 is derived from 3 month of discontinued operation of LSI segment of Jubilant Pharmova Limited on Pro-forma basis

- EPS has been computed on combined profits assuming existence of share capital for full period.